Beckman Coulter Life Sciences Launches Industry-first Infrared Dye Antibody Conjugates To Expand Human Phenotyping Experiments

Trending 2 months ago

Beckman Coulter Life Sciences, a Danaher institution and a world leader successful laboratory automation and innovation, announces nan motorboat of its caller IR820 and IR870 infrared dye antibody conjugates. For nan first time, investigation travel cytometry labs person a debased sound solution, including azygous laser excitation, nary dye interferences on pinch negligible overlap pinch different fluorochome emissions, and ultralow autofluorescence background.

Image Credit: Beckman Coulter Life Sciences

IR820 and IR870 reagents are nan industry’s first straight conjugated antibodies for infrared excitation. The reagents are perfect for lineage marker staining, offering phenomenal brightness to intelligibly place respective gating antigens, while leaving discovery of non-infrared dyes uncompromised owed to near-to-complete absence of spectral overlap. Lineage gating markers now tin beryllium added, aliases if already existing successful nan antibody panel, moved acold distant from commonly utilized spectral ranges wherever typically nan astir precious dim signals reside.

“As high-parameter travel cytometry becomes much mainstream, antibody sheet creation gets moreover much important owed to tightening analyzable spectral interference patterns that tin trim information quality,” said Pietro Lopriore, Vice President and General Manager of nan Flow Cytometry Business Unit. “Our IR820 and IR870 infrared dye conjugates pinch their debased sound creation region complexities and make nan infrared spectral scope a premium spot for lineage markers, allowing for a much elastic antibody sheet design. By enabling greater clarity, we’re capable to uniquely empower researchers successful an breathtaking caller frontier of quality phenotyping experiments.”

Current travel cytometry fluorochrome conjugates do not screen nan infrared range. Lineage markers utilized for recognition of awesome subpopulations typically reside successful nan aforesaid spectral ranges arsenic probes for anemic co-expressed antigens, enabling characterization of subpopulations and their functional status. By this spectral colocalization, typically agleam lineage markers whitethorn discuss solution and delicate discovery of their dimmer co-expressed companions.

We precocious tested nan CD3 IR820 infrared travel cytometry antibody, and we are thoroughly impressed pinch nan results,

By utilizing markers successful these channels, we tin reserve nan different channels for different further markers that are little common, which is important for analyzable multi-parameter assays. Given nan clear separation and minimal interference pinch different channels, we highly urge this infrared antibody for anyone looking to grow their travel cytometry panels.”

Dr. Theo Gerdener, Head of immune phenotyping, ABJ Oncology Pretoria, South Africa

This summation to nan Beckman Coulter Life Sciences reagent portfolio is perfect for users of IR-equipped CytoFLEX LX and S instruments, including spectral pinch nan mosaic discovery module, to widen quality phenotyping experiments into an easy-to-navigate spectral range. IR820 and IR870 are non-tandem dyes which tin beryllium excited astatine 808 nm and emit pinch maximal strength astatine 835 and 896 nm, corresponding to nan 840/20 nm and 885/40 nm aliases akin bandpass filters. The Research Use Only reagents comprise CD3, CD4, CD8, CD14, CD20 and CD45 specificities and are manufactured nether existent bully manufacturing practices.

Citations

Please usage 1 of nan pursuing formats to mention this article successful your essay, insubstantial aliases report:

  • APA

    Beckman Coulter Life Sciences - Flow Cytometry. (2025, September 15). Beckman Coulter Life Sciences launches industry-first infrared dye antibody conjugates to grow quality phenotyping experiments. News-Medical. Retrieved connected September 15, 2025 from https://www.news-medical.net/news/20250915/Beckman-Coulter-Life-Sciences-launches-industry-first-infrared-dye-antibody-conjugates-to-expand-human-phenotyping-experiments.aspx.

  • MLA

    Beckman Coulter Life Sciences - Flow Cytometry. "Beckman Coulter Life Sciences launches industry-first infrared dye antibody conjugates to grow quality phenotyping experiments". News-Medical. 15 September 2025. <https://www.news-medical.net/news/20250915/Beckman-Coulter-Life-Sciences-launches-industry-first-infrared-dye-antibody-conjugates-to-expand-human-phenotyping-experiments.aspx>.

  • Chicago

    Beckman Coulter Life Sciences - Flow Cytometry. "Beckman Coulter Life Sciences launches industry-first infrared dye antibody conjugates to grow quality phenotyping experiments". News-Medical. https://www.news-medical.net/news/20250915/Beckman-Coulter-Life-Sciences-launches-industry-first-infrared-dye-antibody-conjugates-to-expand-human-phenotyping-experiments.aspx. (accessed September 15, 2025).

  • Harvard

    Beckman Coulter Life Sciences - Flow Cytometry. 2025. Beckman Coulter Life Sciences launches industry-first infrared dye antibody conjugates to grow quality phenotyping experiments. News-Medical, viewed 15 September 2025, https://www.news-medical.net/news/20250915/Beckman-Coulter-Life-Sciences-launches-industry-first-infrared-dye-antibody-conjugates-to-expand-human-phenotyping-experiments.aspx.

Terms

While we only usage edited and approved contented for Azthena answers, it whitethorn connected occasions supply incorrect responses. Please corroborate immoderate information provided pinch nan related suppliers or authors. We do not supply aesculapian advice, if you hunt for aesculapian accusation you must ever consult a medical master earlier acting connected immoderate accusation provided.

Your questions, but not your email specifications will beryllium shared with OpenAI and retained for 30 days successful accordance pinch their privateness principles.

Please do not inquire questions that usage delicate aliases confidential information.

Read nan afloat Terms & Conditions.

More